ARTICLE | Company News
NEOT, BMY cancer deal
November 5, 2001 8:00 AM UTC
Neotherapeutics (NEOT) subsidiary NeoOncoRx received worldwide rights to develop and market elsamitrucin from Bristol-Myers Squibb (BMY). NeoOncoRx plans to begin a U.S. Phase II trial of elsamitrucin...